Published on Friday March 10, 2017

Smooth Drug Development February 2017 News Release

The company started new activities:
  • We signed an agreement to prepare a literature review for an antidote drug (Zinci bisvinylimidazoli diacetas)
  • We were awarded with a bioequivalence trial for a combination drug (amlodipine-valsartan-hydrochlorothiazide)
  • We signed an agreement to prepare a literature review for naftifine
  • We are awarded with a bioequivalence trial with a combination drug (Ibuprofen+Pitofenone+Fenpiverinium bromide)
We have reached several milestones in our ongoing trials:
  • Our team is happy to announce that all patients were randomized in two phase II ongoing trials in HDV
  • We have submitted clinical trials application for several trials:
1. A study in Prevention of post-surgery cognitive impairment
2. A study with a drug for a treatment of intrahepatic cholestasis in chronic diffuse liver diseases
3. A study with a drug for a treatment of obstructive jaundice of tumor genesis
4. A study with a drug for a treatment ofbenign obstructive jaundice genesis
  • Enrollment in a phase III trial in URTI is one month ahead of schedule
  • 2 patients were included into a bioequivalence trial with capecitabine
  • Close out was performed in a bioequivalence trial with desmopressin
  • First sites were initiated in a phase III trial in PID
  • All sites in a phase III trial with a contraceptive drug were initiated, 2 patients are randomized